Advertisement
Canada markets closed
  • S&P/TSX

    21,873.72
    -138.00 (-0.63%)
     
  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     
  • DOW

    38,460.92
    -42.77 (-0.11%)
     
  • CAD/USD

    0.7297
    -0.0023 (-0.32%)
     
  • CRUDE OIL

    82.83
    +0.02 (+0.02%)
     
  • Bitcoin CAD

    87,935.16
    -3,110.67 (-3.42%)
     
  • CMC Crypto 200

    1,386.85
    -37.25 (-2.62%)
     
  • GOLD FUTURES

    2,329.10
    -9.30 (-0.40%)
     
  • RUSSELL 2000

    1,995.43
    -7.22 (-0.36%)
     
  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     
  • NASDAQ futures

    17,478.25
    -186.25 (-1.05%)
     
  • VOLATILITY

    15.97
    +0.28 (+1.78%)
     
  • FTSE

    8,040.38
    -4.43 (-0.06%)
     
  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     
  • CAD/EUR

    0.6819
    -0.0017 (-0.25%)
     

Why Shares of Affimed Fell Thursday

Why Shares of Affimed Fell Thursday

Shares of German immuno-oncology company Affimed Therapeutics (NASDAQ: AFMD) were down a little more than 15% on Thursday afternoon. There was no big news from the biotech company, but clinical-stage biotechs are considered riskier stocks than most, and with the markets dropping in general on Thursday, Affimed's shares took a hit. Investors are waiting to hear next month how two clinical trials are faring for one of the company's lead therapies in AFM13.